GlassScriptPhysician profile
Marina Podval
NPI 1982717237
$679.60
in general payments reported to CMS, 2019-2025
15 companies · $84.69 in 2025
The $84.69 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $105 · 2021: $158 · 2022: $31.05 · 2024: $88.25 · 2025: $84.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $172.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $165.06 | 2020-2025 | |
| Horizon Therapeutics Plc | $124.12 | 2019-2022 | |
| Amgen INC. | $63.29 | 2024 | Repatha |
| Lilly USA, LLC | $51.20 | 2019-2021 | |
| Allergan, INC. | $49.38 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $44.85 | 2019-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.29 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.36 | 2025 | Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $17.05 | 2022 | |
| Pfizer INC. | $16.89 | 2019 | |
| Eisai INC. | $16.01 | 2021 | |
| Amarin Pharma, INC. | $14.95 | 2019 | |
| Merck Sharp & Dohme LLC | $14.57 | 2019 | |
| Promius Pharma LLC | $13.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Podval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.